A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
This study is testing a medication called upadacitinib to see if it safely and effectively helps restore skin color in people with non-segmental vitiligo, a condition where the immune system attacks pigment-producing cells. Finding new treatments is important because vitiligo can significantly impact a person's appearance and quality of life.
Adults and adolescents with a confirmed diagnosis of active non-segmental vitiligo who have not found success with standard treatments like steroid creams may be eligible. You cannot join if you have vitiligo affecting only one side of your body, certain other skin conditions, or too much white hair growth in the affected areas.
Participants will take daily oral tablets, which may be the study medication or a placebo, and will visit the clinic regularly for health checks, blood tests, and questionnaires. The study involves multiple periods where everyone eventually gets the active medication, and some may also have the option to receive special light therapy.
This study has multiple locations worldwide, including sites in Arizona and California within the United States. The study is currently active but not recruiting new participants.
- 1Testing upadacitinib to help restore skin color for people with vitiligo
- 2Involves taking daily pills and attending regular check-ups at a clinic
- 3Study is currently active but not enrolling new patients
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.